Catalyst Dossier · compiled by CeliA 🧫

Novo Nordisk A/S (NVO)

Pharmaceutical Preparations · market cap $203.2B · as of 2026-07-13

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-09-01 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Novo Nordisk A/S (NVO) is a Danish pharmaceutical giant with ~68,800 employees and a $203B market cap, controlling positions in diabetes, obesity, cardiovascular, and rare disease. The stock trades at ~$49.48, well below the analyst consensus target of ~$47.66 (mean) to $63.06 (high), with a broad pipeline featuring multiple Phase 3 readouts across 2026–2027, headlined by CagriSema, Cagrilintide, and a Phase 3 ATTR-CM program (NNC6019-0001).

The catalyst path

2026-09-01 (est.)Phase 2 · NNC0519-0130imp 7/10
2026-11-23 (est.)Phase 3 · insulin glargineimp 9/10
2026-12-14 (est.)Phase 2 · NNC0662-0419imp 7/10
2026-12-31 (est.)NDA Filing · Etavopivatimp 8/10
2027-01-01 (est.)Otherimp 6/10
2027-01-14 (est.)Phase 2 · UBT251imp 7/10
2027-03-01 (est.)Phase 3 · CagriSema (Cagrilintide B and Semaglutide I)imp 9/10
2027-05-12 (est.)Phase 3 · Cagrilintideimp 9/10

Pipeline

Asset	Phase	Indication
NNC6019-0001	Phase 3	Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Semaglutide 1.0 mg	Phase 3	Obesity
CDR132L	Phase 2	Heart Failure
biphasic insulin aspart	Phase 3	Diabetes
NNC109-0012	Phase 2	Inflammation
Cagrilintide	Phase 3	Obesity or Overweight
Concizumab	Phase 3	Congenital Bleeding Disorder
sitagliptin	Phase 3	Diabetes
biphasic human insulin	Phase 3	Diabetes
Insulin Icodec	Phase 3	Diabetes Mellitus, Type 2
Semaglutide (administered by PDS290 pen)	Phase 2	Healthy Volunteers Diabetes Mellitus, Type 2
human insulin	Phase 3	Diabetes
insulin 338 (GIPET I)	Phase 2	Diabetes
insulin NPH	Phase 3	Diabetes
metformin	Phase 3	Diabetes
NNC0662-0419	Phase 2	Overweight
turoctocog alfa pegol	Phase 3	Congenital Bleeding Disorder
rosiglitazone	Phase 3	Diabetes
biphasic insulin aspart 50	Phase 3	Diabetes
DPP-4 inhibitor	Phase 3	Diabetes

Price & technical context

3-month

-0.8%

6-month

-11.5%

12-month

-8.8%

52-wk range

$35.29–$63.98

vs 50-day MA

-5.0%

vs 200-day MA

-4.8%

Realized vol

47.2%

Max drawdown

-75.2%

Daily closes through 2026-08-05. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for NVO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.